DataMEDS to supply 6 unapproved peptides to 6,500 pharmacies

More than 6,500 independent pharmacies will have access to six experimental peptides this month. DataMEDS AI, a Nasdaq-listed healthcare company based in Tampa, announced Monday that its subsidiary, Corexa Health, will begin filling prescriptions. The move places the company at the center of a shifting regulatory environment just days after federal health officials altered their stance on these substances.

The six compounds included in the supply deal are BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. None of these peptides have received approval from the Food and Drug Administration for safety or effectiveness. They are short chains of amino acids that some patients seek for potential treatments for inflammation, tissue damage, obesity, and neurological conditions.

The policy shift driving this distribution model occurred on Oct. 30. The U.S. Department of Health and Human Services established a limited path for licensed pharmacies to compound these specific peptides while the FDA continues its review. This allows physicians to prescribe compounded preparations and pharmacists to dispense them under existing federal and state requirements. It creates a structured channel for patients who previously relied on online retailers selling products with research-use-only labels.

Gerald Commissiong, the company’s interim co-CEO, stated that the company aims to bring customers from the gray market into conventional prescription channels. “We believe that many gray market patients would prefer to purchase their peptides from a licensed pharmacy,” Commissiong said. The company intends to manage the logistics of this supply chain through a warehouse in Lakeland.

DataMEDS will use its existing third-party logistics business to handle supplies from manufacturers and distribute them to qualifying compounding pharmacies. The company also plans to utilize its Health Lives Here mobile application to collect and report safety information as required by the new federal policy. Participating pharmacies must meet strict requirements regarding ingredient sourcing, testing, and patient-specific prescriptions.

The FDA’s Pharmacy Compounding Advisory Committee examined these six substances during meetings on July 23 and 24. They considered proposed uses ranging from wound healing to insomnia. Those applications remain unproven, and the current HHS enforcement policy does not grant formal FDA approval. Federal officials retain the ability to change or withdraw the policy at any time.

DataMEDS has not disclosed the financial terms of the supply agreement or the identity of its supplier. The company has not provided estimates for how much revenue the arrangement will generate. The rollout will proceed through Corexa Pharmacy, which operates alongside DataMEDS’s pharmaceutical distribution, technology platforms, and a clinical diagnostics laboratory in Pittsburgh.